Correction: Treatment outcomes of radiotherapy with concurrent weekly cisplatin in older patients with locally advanced head and neck squamous cell carcinoma

Abstract

Correction: Discover Oncology (2023) 14:226https://doi.org/10.1007/s12672-023-00844-7 After publication an error was found by the authors in the progression-free survival (PFS) analysis. Abstract Incorrect The 3-year OS, PFS, and CSS were 80.9% (95% confidence interval [CI]: 64.8–90.7), 68.3% (95% CI 51.8–81.2), and 85.0% (95% CI 68.7–93.4), respectively. Correct The 3-year OS, PFS, and CSS were 80.9% (95% confidence interval [CI]: 64.8–90.7), 58.9% (95% CI: 42.7–73.3), and 85.0% (95% CI: 68.7–93.4), respectively. Results Incorrect With a median follow-up period of 36 months (range: 1–156), the 3-year and 5-year OS rates were 80.9% (95% CI 64.8–90.7) and 69.7% (51.6–83.2), respectively (Fig. 1A). Correct With a median follow-up period of 36 months (range: 1–156), the 3-year and 5-year OS rates were 80.9% (95% CI 64.8–90.7) and 69.7% (51.6–83.2), respectively (Fig. 1A).

Correction: Discover Oncology (2023) 14:226https://doi.org/10.1007/s12672-023-00844-7

After publication an error was found by the authors in the progression-free survival (PFS) analysis. In the original analysis, deaths were not included in the progression-free survival (PFS) analysis as events, as noted in the Methods section. The errors caused by this are listed in this correction article. This analytical error does not affect the interpretation and conclusions of the original article [1].

Abstract

Incorrect

• The 3-year OS, PFS, and CSS were 80.9% (95% confidence interval [CI]: 64.8–90.7), 68.3% (95% CI 51.8–81.2), and 85.0% (95% CI 68.7–93.4), respectively.

Correct

• The 3-year OS, PFS, and CSS were 80.9% (95% confidence interval [CI]: 64.8–90.7), 58.9% (95% CI: 42.7–73.3), and 85.0% (95% CI: 68.7–93.4), respectively.

Results

Incorrect

• With a median follow-up period of 36 months (range: 1–156), the 3-year and 5-year OS rates were 80.9% (95% CI 64.8–90.7) and 69.7% (51.6–83.2), respectively (Fig. 1A). The 3-year and 5-year PFS rates were 68.3% (95% CI 51.8–81.2) and 68.3% (51.8–81.2), respectively, and those for the CSS rates were 85.0% (95% CI 68.7–93.4) and 73.3% (54.5–86.3), respectively (Fig. 1B, C).

• In an analysis limited to 12 patients aged ≥ 75 years, the median follow-up period was 32.5 months (range: 2–77). The 3-year and 5-year OS rates were the same, 87.5% (95% CI 46.3–98.3), and the 3- and 5-year PFS rates were also the same, 53.3% (95% CI 53.3–98.6) (Fig. 2A, B).

Correct

• With a median follow-up period of 36 months (range: 1–156), the 3-year and 5-year OS rates were 80.9% (95% CI 64.8–90.7) and 69.7% (51.6–83.2), respectively (Fig. 1A). The 3-year and 5-year PFS rates were 58.9% (95% CI: 42.7–73.3) and 55.6% (39.4–70.7), respectively, and those for the CSS rates were 85.0% (95% CI: 68.7-93.4) and 73.3% (54.5-86.3), respectively (Fig. 1B, C).

• In an analysis limited to 12 patients aged ≥75 years, the median follow-up period was 32.5 months (range:2-77). The 3-year and 5-year OS rates were the same, 87.5% (95% CI 46.3–98.3), and the 3- and 5-year PFS rates were also the same, 77.1% (95% CI 40.5–94.4) (Fig. 2A, B).

Incorrect

• The median age of the 49 patients was 72 years (range: 70–78) years.

Correct

• The median age of the 49 patients was 72 years (range: 70–78 years).

Incorrect figure 1b

Correct figure 1b

Incorrect figure 2b

Correct figure 2b

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Reference

1. Uchinami, Y; Yasuda, K; Kano, S; Otsuka, M; Hamada, S; Suzuki, T; Tsushima, N; Takahashi, S; Fujita, Y; Miyazaki, T; Higaki, H; Taguchi, J; Shimizu, Y; Sakashita, T; Homma, A; Aoyama, H. Treatment outcomes of radiotherapy with concurrent weekly cisplatin in older patients with locally advanced head and neck squamous cell carcinoma. Discover Oncol; 2023; 14, 226.[COI: 1:CAS:528:DC%2BB3sXisFOqtbjE] [DOI: https://dx.doi.org/10.1007/s12672-023-00844-7]